Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel-AvivUniversity, Tel- Aviv, Israel.
Graefes Arch Clin Exp Ophthalmol. 2021 Jul;259(7):2009-2015. doi: 10.1007/s00417-021-05103-5. Epub 2021 Feb 2.
Changes in the quality of life (QOL) of patients with thyroid eye disease (TED) were examined during a 3-year follow-up in a multidisciplinary eye clinic, and factors that may improve QOL were identified.
A retrospective review of medical records of all patients who attended the TED clinic at Sheba Medical Center, Israel, from May 2016 to May 2019 was performed. The retrieved data included demographics, comprehensive ophthalmic examination findings, clinical activity scores (CAS), laboratory test results, and QOL assessments by the Graves' Orbitopathy QOL (GO-QOL) questionnaire.
One hundred thirty-two TED clinic patients were examined. Thirty patients (22.72%) received medical treatment consisting of steroids according to the European Group on Graves' Orbitopathy (EUGOGO) protocol, high-dose steroids, or immunosuppressive drugs. Twenty-eight patients (21.21%) underwent surgical rehabilitation (decompression, strabismus, or eyelid surgery). There was a significant increase in total QOL score after steroid treatment according to the EUGOGO protocol, after decompression surgery, and after strabismus surgery compared to pre-treatment total QOL (p=0.04, p=0.021, and p=0.042, respectively, matched pairs). In addition, there were significant positive correlations between the changes in the total QOL score and the change in thyroid-stimulating immunoglobulin (TSI) as well as the change in CAS among the patients who underwent medical and surgical interventions.
QOL improved significantly after medical/surgical treatments. A change in the CAS and in the TSI may also correlate with change in QOL. Periodic evaluation of TED patients' QOL is recommended for enhanced and more comprehensive management.
在多学科眼科诊所对甲状腺眼病(TED)患者的生活质量(QOL)进行了 3 年的随访,以检查其变化情况,并确定了可能改善 QOL 的因素。
对 2016 年 5 月至 2019 年 5 月期间在以色列谢巴医疗中心 TED 诊所就诊的所有患者的病历进行了回顾性分析。检索的数据包括人口统计学资料、全面眼科检查结果、临床活动评分(CAS)、实验室检查结果以及使用 Graves 眼病生活质量(GO-QOL)问卷进行的 QOL 评估。
共检查了 132 名 TED 诊所患者。30 名患者(22.72%)接受了根据欧洲 Graves 眼病组(EUGOGO)方案、大剂量类固醇或免疫抑制药物的类固醇治疗。28 名患者(21.21%)接受了手术康复(减压、斜视或眼睑手术)。与治疗前的总 QOL 相比,根据 EUGOGO 方案进行类固醇治疗、减压手术后以及斜视手术后,总 QOL 评分均显著增加(p=0.04、p=0.021 和 p=0.042,配对)。此外,在接受药物和手术干预的患者中,总 QOL 评分的变化与甲状腺刺激免疫球蛋白(TSI)的变化以及 CAS 的变化呈显著正相关。
医学/手术治疗后 QOL 显著改善。CAS 和 TSI 的变化也可能与 QOL 的变化相关。建议定期评估 TED 患者的 QOL,以加强和更全面的管理。